166 related articles for article (PubMed ID: 37452739)
1. Evolution in the frontline treatment of patients with chronic lymphocytic leukemia: experience from one European center.
Arguello-Tomas M; Albiol N; Jara P; Garcia-Cadenas I; Redondo S; Esquirol A; Novelli S; Saavedra S; Martino R; Nomdedeu J; Sierra J; Mora A; Moreno C
Leuk Lymphoma; 2023 Oct; 64(10):1655-1661. PubMed ID: 37452739
[TBL] [Abstract][Full Text] [Related]
2. Selecting Frontline Therapy for CLL in 2018.
Jain N
Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):242-247. PubMed ID: 30504317
[TBL] [Abstract][Full Text] [Related]
3. Frontline Therapy in Chronic Lymphocytic Leukemia.
Arguello-Tomas M; Albiol N; Moreno C
Acta Haematol; 2024; 147(1):47-59. PubMed ID: 37899041
[TBL] [Abstract][Full Text] [Related]
4. Frontline treatment with the combination obinutuzumab ± chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group.
Herishanu Y; Shaulov A; Fineman R; Bašić-Kinda S; Aviv A; Wasik-Szczepanek E; Jaksic O; Zdrenghea M; Greenbaum U; Mandac I; Simkovic M; Morawska M; Benjamini O; Spacek M; Nemets A; Bairey O; Trentin L; Ruchlemer R; Laurenti L; Stanca Ciocan O; Doubek M; Shvidel L; Dali N; Mirás F; De Meûter A; Dimou M; Mauro FR; Coscia M; Bumbea H; Szász R; Tadmor T; Gutwein O; Gentile M; Scarfò L; Tedeschi A; Sportoletti P; Gimeno Vázquez E; Marquet J; Assouline S; Papaioannou M; Braester A; Levato L; Gregor M; Rigolin GM; Loscertales J; Medina Perez A; Nijziel MR; Popov VM; Collado R; Slavutsky I; Itchaki G; Ringelstein S; Goldschmidt N; Perry C; Levi S; Polliack A; Ghia P
Am J Hematol; 2020 Jun; 95(6):604-611. PubMed ID: 32096887
[TBL] [Abstract][Full Text] [Related]
5. Real world risk of infusion reactions and effectiveness of front-line obinutuzumab plus chlorambucil compared with other frontline treatments for chronic lymphocytic leukemia.
Bourrier N; Landego I; Bucher O; Squires M; Streu E; Hibbert I; Whiteside T; Gibson SB; Geirnaert M; Johnston JB; Dawe DE; Banerji V
BMC Cancer; 2022 Feb; 22(1):148. PubMed ID: 35123433
[TBL] [Abstract][Full Text] [Related]
6. Chlorambucil for the treatment of patients with chronic lymphocytic leukemia (CLL) - a systematic review and meta-analysis of randomized trials.
Vidal L; Gurion R; Ram R; Raanani P; Bairey O; Robak T; Gafter-Gvili A; Shpilberg O
Leuk Lymphoma; 2016 Sep; 57(9):2047-57. PubMed ID: 26980554
[TBL] [Abstract][Full Text] [Related]
7. [Current diagnosis and treatment of chronic lymphocytic leukaemia].
Cramer P; von Tresckow J; Eichhorst B; Hallek M
Dtsch Med Wochenschr; 2020 Aug; 145(16):1139-1144. PubMed ID: 32791549
[TBL] [Abstract][Full Text] [Related]
8. Past, present and future role of chlorambucil in the treatment of chronic lymphocytic leukemia.
Goede V; Eichhorst B; Fischer K; Wendtner CM; Hallek M
Leuk Lymphoma; 2015 Jun; 56(6):1585-92. PubMed ID: 25219593
[TBL] [Abstract][Full Text] [Related]
9. Impact of age on outcomes after initial therapy with chemotherapy and different chemoimmunotherapy regimens in patients with chronic lymphocytic leukemia: results of sequential cancer and leukemia group B studies.
Woyach JA; Ruppert AS; Rai K; Lin TS; Geyer S; Kolitz J; Appelbaum FR; Tallman MS; Belch AR; Morrison VA; Larson RA; Byrd JC
J Clin Oncol; 2013 Feb; 31(4):440-7. PubMed ID: 23233702
[TBL] [Abstract][Full Text] [Related]
10. Single-agent ibrutinib versus chemoimmunotherapy regimens for treatment-naïve patients with chronic lymphocytic leukemia: A cross-trial comparison of phase 3 studies.
Robak T; Burger JA; Tedeschi A; Barr PM; Owen C; Bairey O; Hillmen P; Simpson D; Grosicki S; Devereux S; McCarthy H; Coutre SE; Quach H; Gaidano G; Maslyak Z; Stevens DA; Moreno C; Gill DS; Flinn IW; Gribben JG; Mokatrin A; Cheng M; Styles L; James DF; Kipps TJ; Ghia P
Am J Hematol; 2018 Nov; 93(11):1402-1410. PubMed ID: 30129285
[TBL] [Abstract][Full Text] [Related]
11. Frontline Treatment for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Targeted Therapy vs. Chemoimmunotherapy.
Small S; Ma S
Curr Hematol Malig Rep; 2021 Aug; 16(4):325-335. PubMed ID: 34021874
[TBL] [Abstract][Full Text] [Related]
12. Impact of gene mutations and chromosomal aberrations on progression-free survival in chronic lymphocytic leukemia patients treated with front-line chemoimmunotherapy: Clinical practice experience.
Spunarova M; Tom N; Pavlova S; Mraz M; Brychtova Y; Doubek M; Panovska A; Skuhrova Francova H; Brzobohata A; Pospisilova S; Mayer J; Trbusek M
Leuk Res; 2019 Jun; 81():75-81. PubMed ID: 31054420
[TBL] [Abstract][Full Text] [Related]
13. Real-world data on efficacy and safety of obinutuzumab plus chlorambucil, rituximab plus chlorambucil, and rituximab plus bendamustine in the frontline treatment of chronic lymphocytic leukemia: The GO-CLLEAR Study by the Czech CLL Study Group.
Panovská A; Němcová L; Nekvindová L; Špaček M; Šimkovič M; Papajík T; Brejcha M; Lysák D; Zuchnická J; Novák J; Starostka D; Poul H; Vrbacký F; Vodárek P; Urbanová R; Plevová K; Pospíšilová Š; Mašlejová S; Brychtová Y; Koriťáková E; Smolej L; Doubek M
Hematol Oncol; 2020 Oct; 38(4):509-516. PubMed ID: 32400885
[TBL] [Abstract][Full Text] [Related]
14. [Treatment strategies for chronic lymphocytic leukemia in the era of novel targeted therapies].
Kojima K
Rinsho Ketsueki; 2020; 61(9):1275-1280. PubMed ID: 33162526
[TBL] [Abstract][Full Text] [Related]
15. Bendamustine versus chlorambucil in treatment of chronic lymphocytic leukaemia in China: a randomized, open-label, parallel-controlled, phase III clinical trial.
Zhou D; Xu W; Ma H; Zhao C; Hu Y; Zhao Y; Wu D; Zhao X; He Y; Yan J; Wang C; Meng F; Jin J; Zhang X; Yu K; Hu J; Lv Y
Invest New Drugs; 2022 Apr; 40(2):349-360. PubMed ID: 35031896
[TBL] [Abstract][Full Text] [Related]
16. Comparative Efficacy of Acalabrutinib in Frontline Treatment of Chronic Lymphocytic Leukemia: A Systematic Review and Network Meta-analysis.
Davids MS; Waweru C; Le Nouveau P; Padhiar A; Singh G; Abhyankar S; Leblond V
Clin Ther; 2020 Oct; 42(10):1955-1974.e15. PubMed ID: 33032842
[TBL] [Abstract][Full Text] [Related]
17. Real-world Clinical Outcomes of First-Line Ibrutinib or Chemoimmunotherapy in Patients with Chronic Lymphocytic Leukemia by Risk Status.
Huang Q; Deering KL; Harshaw Q; Leslie LA
Adv Ther; 2022 Jul; 39(7):3292-3307. PubMed ID: 35608754
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of the obinutuzumab-chlorambucil combination in the frontline treatment of elderly CLL patients with comorbidities - Polish Adult Leukemia Group (PALG) real-life analysis.
Długosz-Danecka M; Jurczak W; Łątka-Cabała E; Morawska M; Gawroński K; Wiśniewska A; Dudziński M; Wąsik-Szczepanek E; Chmielowska E; Łabędź A; Wdowiak K; Hus I
Pol Arch Intern Med; 2018 Aug; 128(7-8):421-426. PubMed ID: 30057377
[TBL] [Abstract][Full Text] [Related]
19. A five-year follow-up of untreated patients with chronic lymphocytic leukaemia treated with ofatumumab and chlorambucil: final analysis of the Complement 1 phase 3 trial.
Offner F; Robak T; Janssens A; Govind Babu K; Kloczko J; Grosicki S; Mayer J; Panagiotidis P; Schuh A; Pettitt A; Montillo M; Werner O; Vincent G; Khanna S; Hillmen P
Br J Haematol; 2020 Sep; 190(5):736-740. PubMed ID: 32236950
[TBL] [Abstract][Full Text] [Related]
20. IGHV mutational status and outcome for patients with chronic lymphocytic leukemia upon treatment: a Danish nationwide population-based study.
Rotbain EC; Frederiksen H; Hjalgrim H; Rostgaard K; Egholm GJ; Zahedi B; Poulsen CB; Enggard L; da Cunha-Bang C; Niemann CU
Haematologica; 2020 Jun; 105(6):1621-1629. PubMed ID: 31582540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
